Reading in the Daily telegraph from London yesterday:

A financial adviser, Mr Haefele from UBS believes that the focus for investors should be in emerging markets health care and above all oncology and immunotherapy, a sector which apparently has 300 clinical trials running with treatments cost in excess of $100,000 per patient.

He points out that spending per cancer patient jumped 60% in the US, Canada and Germany from 2010 to 2014. This pattern is likely to be repeated, over time, in East Asia and Latin America.

For New Zealand, this trend in healthcare costs highlights the importance of having private health insurance as part of the risk management strategy and especially insurance for non Pharmac funded drugs